8-K: Adicet Bio's ADI-001 Shows Strong Tissue Trafficking and Complete B Cell Depletion in Clinical Trial

Adicet Bio announced positive clinical biomarker data for ADI-001, demonstrating robust tissue trafficking and complete B cell depletion in secondary lymphoid tissue, suggesting potential as a best-in-class therapy for autoimmune diseases.

Summary

• Adicet Bio has released clinical biomarker data from the Phase 1 GLEAN trial for their ADI-001 therapy.
• The data shows that ADI-001 exhibits significant levels of CAR T cell activation and tissue exposure in lymph node biopsies.
• A mean exposure of 236,701 CAR T cells per million was observed across all dose levels, with a range of 27-64% of total cellular material detected at the 1E9 dose.
• This exposure exceeds levels previously reported for patients receiving autologous alpha-beta CAR T therapies.
• The CAR T cells also demonstrated a robust activation profile, indicated by the presence of granzyme B.
• Importantly, ADI-001 achieved complete depletion of CD19+ B cells within analyzed secondary lymphoid tissue.
• This is significant because other therapies targeting CD20 have failed to deplete B cells in these tissues.
• These results support ADI-001's potential for achieving complete B-cell depletion in both peripheral blood and tissues.
• Adicet is advancing ADI-001 in clinical programs for lupus nephritis, systemic lupus erythematosus, systemic sclerosis, and anti-neutrophil cytoplasmic autoantibody associated vasculitis.
• Initial clinical data for these autoimmune indications is expected in the first half of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with strong potential for ADI-001, suggesting a high likelihood of success. The results are better than existing therapies and the company is moving forward with clinical trials in multiple autoimmune indications. However, there are still risks associated with clinical trials and regulatory approvals.

Positives

• ADI-001 shows strong tissue trafficking, indicating it can reach the areas where it needs to work.
• The therapy demonstrates significant CAR T cell activation, suggesting it is effectively engaging with the target cells.
• Complete B cell depletion in secondary lymphoid tissue is a key advantage over existing therapies.
• The high levels of CAR T cell exposure in tissues are promising.
• The therapy is being developed for multiple autoimmune diseases, expanding its potential market.
• Initial clinical data for autoimmune indications is expected in the first half of 2025.

Risks

• The company's ability to execute its strategy, including obtaining regulatory approvals, is subject to risk.
• Positive results from early studies may not predict future outcomes.
• Clinical studies may not demonstrate adequate safety and efficacy.
• Regulatory approval processes are lengthy and unpredictable.
• The company's ability to meet production and product release expectations is not guaranteed.
• Global economic conditions and public health crises could impact the company's business and financial results.

Future Outlook

Adicet expects to report initial clinical data for ADI-001 in four autoimmune indications in the first half of 2025, and is advancing the clinical program in lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis.

Management Comments

• Dr. Blake Aftab, Chief Scientific Officer of Adicet Bio, stated that the results support the potential of ADI-001 and Adicet's off-the-shelf gamma delta CAR T cell platform.
• Dr. Aftab also highlighted that the findings provide multiple levels of evidence highlighting the significant advantages of their approach and present a compelling opportunity for ADI-001 to extend B cell targeting into tissues.

Industry Context

This announcement is significant in the context of the broader cell therapy field, particularly for autoimmune diseases. The ability of ADI-001 to achieve complete B cell depletion in secondary lymphoid tissue, where other therapies have failed, could position it as a leading treatment option. The use of allogeneic gamma delta T cells also represents a novel approach compared to traditional alpha-beta CAR T therapies.

Comparison to Industry Standards

• The reported mean exposure of 236,701 CAR T cells per million for ADI-001 exceeds levels previously reported for patients who received autologous alpha-beta CAR T therapies, suggesting a potential advantage in efficacy.
• While anti-CD20 targeted antibodies have shown depletion of B cells in peripheral blood, they have failed to deplete B cells within secondary lymphoid tissues, a limitation that ADI-001 appears to overcome.
• Companies like Gilead (Yescarta, Tecartus) and Novartis (Kymriah) have established autologous CAR T therapies for cancer, but ADI-001's allogeneic approach and focus on autoimmune diseases differentiate it from these established players.
• The ability of ADI-001 to achieve complete B cell depletion in secondary lymphoid tissue is a key differentiator compared to other therapies in development for autoimmune diseases.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data.
• Patients with autoimmune diseases may benefit from the development of a new and potentially more effective therapy.
• Employees may be motivated by the positive results and the potential for the company's success.
• The company's success could lead to increased business for suppliers and partners.

Next Steps

• Adicet will continue to advance the ADI-001 clinical program in lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis.
• The company expects to report initial clinical data in the first half of 2025.

Key Dates

Keywords

ADI-001, CAR T cell therapy, allogeneic cell therapy, autoimmune disease, B cell depletion, tissue trafficking, lymphoid tissue, clinical trial, biomarker data, gamma delta T cells